Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), announces that on January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation (“GPCR”), pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation (“GPCR USA”). GPCR USA is a biotech company that is currently led by Dr. Pina Cardarelli, the CSO and president of GPCR USA. The company has an ongoing Phase 2 clinical trial focused on blood cancer patients, particularly those eligible for hematopoietic stem cell transplantation (HSCT).
Read the full article: Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. //
Source: https://www.businesswire.com/news/home/20250122516457/en/Exicure-Inc.-Announces-Purchase-Agreement-with-GPCR-Therapeutics-Inc.